“In the ongoing global randomized controlled trials of the Oxford coronavirus vaccine, our popular review procedure was activated and we voluntarily discontinued vaccination to allow review of protection knowledge through an independent committee,” said a spokesperson for AstraZeneca, the drug manufacturer that works with the University of Oxford. – said.
They explained that it was a “routine action” and that it accelerates the investigation to minimize any possible effect on the timing of the trial.
“We are committed to ensuring the protection of our participants and the highest criteria for conducting our trials,” they added.
Health Secretary Matt Hancock told Sky News’s Kay Burley that the hiatus wasn’t necessarily fear and that she had already overcome one of the delays.
“It is obviously a challenge to this particular vaccine,” he says.
“This is not the first time this has happened to the Oxford vaccine and it is a procedure in clinical trials. “
When asked if it was a setback, Hancock replied: ‘Not necessarily, it depends on what they find when they do the research.
“There was a hiatus earlier this summer and it was resolved without a hitch. “
Lately the nature of the adverse reaction and when it occurred is known.
Clinical stoppages mean there is a hiatus in recruiting new participants and dosing existing participants.
It’s not unusual for trials to be suspended, but scientists are struggling to expand a vaccine to stop the pandemic.
Most of the serious side effects that occur after vaccination are unrelated to the injection and are incidental physical fitness problems, the World Health Organization (WHO) said.
When a vaccine is given to a large number of other people, chances are that some other people will delight in a medical challenge at the time of vaccination; however, this is not a cause and effect.
Still, researchers will have to investigate whether there is a link.
In July, the first effects of the trial showed that the vaccine was and produced strong immune responses in volunteers.
No unforeseen side effects were recorded at that time, more than a portion of the 1,000 participants reported mild or moderate side effects, adding fever, headache, muscle pain, and muscle aches at the site. injection.
Phase 3 trials of the Oxford vaccine had expanded to the United States, recruiting up to 30,000 adults.
Trials were underway in South Africa and Brazil.
Experts say that locating a vaccine is the only way the world can go back to general in the future, and lately there are nine candidate vaccines in larger phase 3 trials.
But it’s not clear how well a vaccine will work, and infectious disease expert US Dr. Anthony Fauci recently warned that the chances of it being nearly 100 percent effective are “not great. “
“We still don’t know what the effectiveness might be. We don’t know if it will be 50% or 60%. I’d like it to be 75% or more, ”he said.